



## Research Article

The work is licensed under



## Seroprevalence of Hepatitis B Markers in Iraqi Patients with Chronic Hepatitis B Virus

Shiamaa G.Abid<sup>1</sup>, Rana S.Aboud<sup>1\*</sup>, Anmar Saadi Aboud<sup>2</sup>

<sup>1</sup>Biology department, College of Science, University of Baghdad. Baghdad-Al-Jadiria, Iraq

<sup>2</sup>Biology department, College of Science, University of Al-mustansaria, Baghdad, Iraq

\*Corresponding Author: Rana S.Aboud, Biology department, College of Science, University of Baghdad. Baghdad-Al-Jadiria, Iraq

Received: 26 November 2016

Revised: 06 June 2017

Accepted: 12 June 2017

### ABSTRACT

To determine the seroprevalence of hepatitis B markers in chronic hepatitis B patients, seventy-five patients with chronic hepatitis B virus of ages (8-70) years have been investigated and compared with 50 apparently healthy individuals. All the studied groups were carried out to measure (HBsAg), (HBsAb), (HBeAg), (HBeAb), and (Total HBcAb) by Enzyme linked immunosorbent assay (ELISA) technique. The percentage distribution of HBsAg was (86.67%) and HBsAb was (1.33%) in sera of CHB patients and there were a highly significant differences ( $P < 0.01$ ) when compared between studied groups, while, the percentage distribution of HBeAg was (22.67%) in sera of CHB patients and the significant represent the difference in distribution of HBeAg as infection but not as HBsAg distribution. Whereas the percentage distribution of HBeAb was (50.67%) in sera of CHB patients and there were no significant differences ( $P > 0.05$ ) when compared between the studied group. The statistical analysis also demonstrated that the percentage distribution of total HBc Ab was (73.33%) in sera of CHB patients and there were a highly significant differences ( $P < 0.01$ ) when compared between studied group. These results indicated that HBsAg was the predominant markers in patients with chronic hepatitis B virus.

**Keyword:** Hepatitis B virus; HBsAg; HBsAb; HBeAg; HBeAb; Total HBcAb

### INTRODUCTION

Hepatitis B is an infectious inflammatory illness of the liver caused by the hepatitis B virus (HBV) that affects hominoidea, including humans, originally known a serum hepatitis. The disease has caused epidemics in parts of Asia and Africa, and it is endemic in China [1].

Hepatitis B virus, abbreviated HBV, is a species of the genus *Orthohepadna-virus*, which is likewise a part of the *Hepadnaviridae* family of viruses [2], 42 nm DNA virus and has a partially double-stranded DNA genome and contains a core antigen (HBcAg) surrounded by a shell

containing surface antigen (HBsAg). The virus is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes presented on its envelope proteins, and into eight genotypes (A-H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus [3]. Chronic hepatitis B infection is a major cause of chronic liver disease worldwide, each phase of hepatitis B infection stimulates distinct viral kinetics and host immune responses

resulting in liver damage and hepatic fibrosis [4]. The first phase of chronic hepatitis Immune Tolerant Phase: is more frequent and prolonged in perinatally-infected patients via perinatal transmission from HBeAg-positive mothers [5] or those infected in the early years of life. It is characterized by HBeAg positivity, high levels of HBV replication, normal or low levels of aminotransferases, and mild or no liver involvement. Immune Reactive Phase, This phase may occur after several years of immune tolerance and is more frequently observed in patients infected during adulthood. It is characterized by HBeAg positivity, a lower level of HBV replication, increased or fluctuating levels of aminotransferases [6]. Inactive HBV Carrier State: This phase may follow seroconversion from HBeAg positive to anti-HBe antibody positive. It is characterized by very low or undetectable serum HBV DNA levels and normal aminotransferases [7]. HBeAg-Negative Chronic Hepatitis B: This phase may follow HBeAg seroconversion during the immune reactive phase and represents a later stage in the natural history of chronic hepatitis B. It is characterized by periodic reactivation with a pattern of fluctuating levels of HBV DNA and aminotransferases and active hepatitis [8]. Hepatitis B Surface Antigen (HBsAg) Negative Phase: Low levels of HBV replication may still occur in the liver after the loss of HBsAg, HBsAg loss is associated with improvement in outcome with a lowered risk of cirrhosis, decompensation, and hepatocellular carcinoma, immunosuppression can lead to reactivation in these patients [9,10]. The aim of present study was to determine the prevalence of hepatitis B virus markers in Iraqi patients with chronic hepatitis B virus.

## MATERIALS AND METHODS

### Patient's samples

The study was selected of seventy-five patients positively to chronic hepatitis B virus that attended to hepatic and gastrointestinal tract hospital from different capitals in Iraq during the period from first of November 2013 until February 2014. The ages of the total patients were ranged from (8-70) years.

### Control samples

Fifty samples of healthy individuals; 23 female and 27 male were studied as a control group of

same ages and sex. All samples were marked by the number of samples, the name of patient and day of sample collection.

### Blood samples collection

Blood samples (5ml) were collected by disposable syringe into gel tubes and stand at room temperature until the coagulant was formed. Then the samples were centrifuged at 3000 rpm for 5 minutes. Serum samples were dispensed separated on a seven Ependroff tubes. All samples were marked by the name, day and numbering and stored at (-20°C) until carried out to examination.

### Serological markers

All the study group was carried out to measurement of hepatitis B markers ( HBsAg), (HBsAb), (HBeAg), (HBeAb), and(Total HBcAb) with the aid of commercially available Enzyme-linked immunosorbent assay (ELISA) kit foresight, USA according to the leaflets of kits [11].

### STATISTICAL ANALYSIS

The statistical analysis used included Student t-test and Pearson chi-square test (x<sup>2</sup>). The Statistical Package for Social Science V.13 (SPSS) was used. A p-value <0.05 was considered statistically significant [12].

### RESULTS AND DISCUSSION

The percentage distribution of HBsAg was (86.67%) and HBsAb was (1.33%) in sera of CHB patients and there were a highly significant differences (P<0.01) when compared between studied groups as shown in the table (1). Mean while the percentage distribution of HBeAg was (22.67%) in sera of CHB patients and the significant represent the difference in the distribution of HBeAg as an infection but not as HBsAg distribution. Whereas the percentage distribution of HBeAb was (50.67%) in sera of CHB patients and there were no significant differences (P>0.05) when compared between studied groups as shown in the table 2. The statistical analysis also demonstrated that the percentage distribution of total HBc Ab was (73.33%) in sera of CHB patients and there were a highly significant differences (P<0.01) when compared between studied groups as shown in the table 3.

**Table 1: The percentage distribution of HBsAg and HBsAb in sera of CHB patients**

Test	HBs Ag		HBs Ab	
	No.	%	No.	%
Positive	65	86.67	1	1.33
Negative	10	13.33	74	98.67
Total	75	100 %	75	100 %
Chi-square value	---	13.781 **	---	15.833 **

\*\* (P&lt;0.01)

**Table 2: The percentage distribution of HBeAg and HBeAb in sera of CHB patients**

Test	HBeAg		HBeAb	
	No.	%	No.	%
Positive	17	22.67	38	50.67
Negative	58	77.33	37	49.33
Total	75	100 %	75	100 %
Chi-square value	---	11.962 **	---	0.351 NS

\*\* (P&lt;0.01)

**Table 3: The percentage distribution of HBcAb in sera of CHB patients**

Test	Total HBcAb	
	No.	%
Positive	55	73.33
Negative	20	26.67
Total	75	100 %
Chi-square value	---	11.026 **

\*\* (P&lt;0.01)

The results of the current study was close to the findings of other studies done by Zafaret *al* [13] who identified the percentages for HBsAg, HBeAb and HBcAb were 42.5%, 50.3%, and 59%, respectively, while HBeAg 31% and HBsAb was 50.6% and Chen [14] who identified percentage of HBsAg was 53.6%. Our results disagreed with Al-Hajilisa [15] who reported the percentage of HBsAg 14%, HBeAg 20% and 80% for HBeAb. Wang *et al* [16] reported the prevalence of HBsAg and HBeAg was 6.1% and 4.8%, respectively, while HBeAb was 89.1% and 18.8% for total HBcAb which were incompatible with our results. In Indonesia, 4.6% of the population was positive for HBsAg in 1994 and of these, 21% were positive for HBeAg and 73% for anti-HBeAb 44% and 45% of Indonesian patients with cirrhosis and HCC, respectively, were HBsAg positive. HBeAg was found in 14.3% of patients with chronic hepatitis B in Turquia [17], 30% in Campinas in southeastern Brazil [18] and 37.3% in RioGrandedoSul in southern Brazil [19]. The differences in the results may be related to the size of the sample and the technical methods that were used in the diagnosis of

infection. Previous studies have suggested that quantitative hepatitis B surface antigen (HBsAg) is also a surrogate marker that can be used to monitor patients with CHB who are being treated [20]. There are two forms of HBsAg-one over intact virion, which includes small, medium, and large proteins in envelopes and is related to viral infectivity, and another that exists as subviral particles in serum and is produced in great excess. These are predominantly S protein and, to a lesser extent, M and L protein; these are not infectious but are strongly immunogenic, stimulating antibody production [21]. Antibody to surface antigen (anti-HBs) this is a protective antibody that develops with the resolution of acute infection or following the successful vaccination against HBV. Very occasionally, anti-HBs and HBsAg can be found together, which has no known clinical significance [22]. Hepatitis Be antigen (HBeAg) is an accessory protein from the pre-core region of the HBV genome, which is not necessary for viral infection or replication. It is, however, produced during active viral replication and may act as an immunogen or tolerogen, leading to persistent infection. In HBeAg-positive

patients, the HBsAg levels were distributed in a triphasic-like decline pattern by two logs across age strata. Chronic hepatitis B virus (CHB) can be broadly divided into two major forms-namely, hepatitis B virus e antigen (HBeAg) positive and HBeAg negative [23]. Antibody to e antigen (anti-HBe) while, is not a protective antibody, its appearance usually coincides with a significant immune change associated with lower HBVDNA replication (<105 copies/mL or 20,000 IU/ml). The loss of HBeAg and the development of anti-HBe is termed HBeAg seroconversion and has been used as an end-point for treatment in HBeAg-positive people, as it has been shown that seroconversion is associated with a lower risk of disease progression [24]. Antibody to core antigen (anti-HBc), the HBV core antigen is not found as a discrete protein in the serum but it is produced in the hepatocyte cytosol during HBV replication, surrounding the viral genome and the associated polymerase. It is then packaged within an envelope before secretion from the hepatocyte [22]. The antibody to HBV core (anti-HBc) is an antibody to a peptide of this core protein, which has been processed within an antigen presenting cell. Anti-HBcIgG remains positive for life following exposure to HBV, however, unlike anti-HBs, anti-HBc is not a protective antibody. Most serological assays do not directly measure anti-HBcIgG, but test for total anti-HBc antibody [25].

## CONCLUSION

These results indicated that HBsAg was the predominant markers in patients with chronic hepatitis B virus.

## CONFLICT OF INTEREST STATEMENT

The authors declare that they have no conflict of interests.

## REFERENCES

1. Westerberg D. New strategies for diagnosis and management of celiac disease. *New Engl J Med* 2006; 106 (3):145-151.
2. Hunt and Richard. Hepatitis viruses. California: Department of pathology and Microbiology, the University of Southern California; 2007, p 2280.
3. Stein LL, Lumda R. Drug targets in hepatitis B virus infection. *Infect Dis Drug Tar* 2009; 9(2):105-116.
4. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. *New Engl J Med* 2004; 350(11): 1118-1129.
5. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH. Clearance of hepatitis Be antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. *Gastroenterol* 2007; 133:1452-1457.
6. Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007; 45:507- 539.
7. McMahon BJ. Epidemiology and natural history of hepatitis B. *Semin Liver Dis* 2005; 25(1):3-8.
8. Funk ML, Rosenberg DM, Lok AS. Worldwide epidemiology of HBeAg negative chronic hepatitis B and associated precore and core promoter variants. *J Viral Hepatol* 2002; 9: 52-61.
9. Manno M, Camma C, Schepis F, Bassi F, Gelmini R, Giannini F. Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years. *Gastroenterol* 2004; 127:756-763.
10. Easl Clinical Practice Guidelines. Management of chronic hepatitis B. *J Hepatol* 2009; 50(2): 227-242.
11. Dienstag JL. Hepatitis B virus infection. *New Engl J Med* 2008; 359:1486-1500.
12. SAS. Statistical Analysis System, User's Guide. Statistical. Version 9.1<sup>th</sup> ed. N.C. USA: SAS Inst. Inc. Cary; 2012.
13. Zafar A, Khan E, Khan MS, Moiz B, Jafir W. Changing trends of Hepatitis B sero-markers amongst Pakistani population: A laboratory-based review. *J Pak Med Asso* 2013; 63: 826-830.
14. Chen NL, Bai L, Deng T, Zhang C, Kong QY, Chen H. Expression of hepatitis B virus antigen and Helicobacter pylori infection in gastric mucosa of patients with chronic liver disease. *HBPD Int* 2004; 3(2):223-225.
15. Al-HajiIsa M, Bello HS, Shettima A, Allamin A. Prevalence of serological markers for chronic hepatitis B among patients attending Skoto, Nigeria. *J Microbiol Biotech Res* 2013; 3(3):122-125.
16. Wang YB, Chen EQ, Cui YL, Zeng L, Wang YJ, Tang H. Seroprevalence of hepatitis B virus markers in individuals for physical

- examination in West China Hospital. *Eur Rev Med Pharm Sci* 2011; 15: 592-596.
17. Altinbas A, Aktas B, Basar O, Yüksel O, Ekiz F, Yilmaz B. Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection? *Ann Hepatol* 2012; 11(3):320-325.
  18. Tonetto PA, Gonçalves NS, Fais VC, Vigani AG, Gonçalves ES, Feltrin A. Hepatitis B virus: Molecular genotypes and HBeAg serological status among HBV-infected patients in the southeast of Brazil. *BMC Infect Dis* 2009; 9:149
  19. Becker CE, Mattos AA, Bogo MR, Branco F, Sitnik R, Kretzmann NA. Genotyping of hepatitis B virus in a cohort of patients evaluated in a hospital of Porto Alegre, south of Brazil. *Arq Gastroenterol* 2010; 47:13-17.
  20. Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. *Dig Dis Sci* 2008; 53(11):2995-2998.
  21. Ganji A, Esmaeilzadeh A, Ghafarzadegan K, Helalat H, Rafatpanah H, Mokhtarifar A. Correlation between HBsAg quantitative assay results and HBV. *Hepat Mon* 2011; 11(5):342-345.
  22. Hassanein T. Screening and diagnosis in hepatitis B virus infection: Immigrant and special populations. *Adv Stud Med* 2009; 9(3):82-88.
  23. Milich D, Liang TJ. Exploring the biological basis of hepatitis Be antigen in hepatitis B virus infection. *Hepat* 2003; 38 :1075-1086.
  24. Chen YS, Liang XF, Hu JF. The serum markers of hepatitis B virus (HBV) infection and the natural history of chronic HBV infection. *Zhongguo Yi Miao He Mian Yi* 2009; 15(3):279-283.
  25. Vagro P, Veropalumbo C, Maddaluno S, Salerno M, Parenti G, Pignata C. Treatment of children with chronic viral hepatitis: what is available and what is in store. *World J Pediatr* 2013; 9(3):212-220.

**Cite this article as:**

Shiamaa G. Abid, Rana S.Aboud, Anmar Saadi Aboud. Seroprevalence of Hepatitis B Markers in Iraqi Patients with Chronic Hepatitis B Virus. *J Pharm Chem Biol Sci* 2017; 5(2): 92-96.